EKSO GT™ ROBOTIC EXOSKELETON CLEARED BY FDA FOR USE WITH STROKE AND SPINAL CORD INJURY PATIENTS

First robotic exoskeleton cleared for use with stroke and spinal cord injury levels to C7

RICHMOND, Calif., April 5 (Bernama-GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a robotic exoskeleton company, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its Ekso GT robotic exoskeleton for use in the treatment of individuals with hemiplegia due to stroke, individuals with spinal cord injuries at levels T4 to L5, and individuals with spinal cord injuries at levels of T3 to C7 (ASIA D), in accordance with device’s labeling. The Ekso GT is the first exoskeleton cleared by the FDA for use with stroke patients.  

http://mrem.bernama.com/viewsm.php?idm=26543